MetaVia Inc
Company Profile
Business description
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Contact
545 Concord Avenue
Suite 210
CambridgeMA02138
USAT: +1 857 702-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,765.20 | 74.30 | 0.85% |
| CAC 40 | 7,763.84 | 26.64 | 0.34% |
| DAX 40 | 24,091.62 | 160.95 | 0.67% |
| Dow JONES (US) | 42,519.64 | 214.16 | 0.51% |
| FTSE 100 | 8,787.02 | 12.76 | 0.15% |
| HKSE | 23,682.34 | 169.85 | 0.72% |
| NASDAQ | 19,398.96 | 156.34 | 0.81% |
| Nikkei 225 | 37,813.92 | 367.11 | 0.98% |
| NZX 50 Index | 12,447.37 | 120.14 | 0.97% |
| S&P 500 | 5,970.37 | 34.43 | 0.58% |
| S&P/ASX 200 | 8,539.10 | 72.40 | 0.86% |
| SSE Composite Index | 3,376.53 | 14.56 | 0.43% |